Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap USD M258Revenue (TTM) USD M0.7Net Margin (%)-4,439.9Altman Z-Score16.7
Enterprise Value USD M204EPS (TTM) USD -0.6Operating Margin %-4,563.9Piotroski F-Score2
P/E(ttm)--Beneish M-Score6.9Pre-tax Margin (%)-4,437.1Higher ROA y-yN
Price/Book4.610-y EBITDA Growth Rate %1.1Quick Ratio10.6Cash flow > EarningsY
Price/Sales4215-y EBITDA Growth Rate %7.5Current Ratio10.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-40.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-45.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M51.1ROIC % (ttm)-259.4Gross Margin Increase y-yN

Gurus Latest Trades with CGEN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CGEN is held by these investors:



CGEN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about CGEN:

    News about CGEN:

    Articles On GuruFocus.com
    Compugen Reports First Quarter 2017 Results May 09 2017 
    Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO May 04 2017 
    Compugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET Apr 26 2017 

    More From Other Websites
    Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session May 22 2017
    Investor Network: Compugen Ltd. to Host Earnings Call May 09 2017
    Compugen reports 1Q loss May 09 2017
    Compugen Reports First Quarter 2017 Results May 09 2017
    Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO May 04 2017
    Compugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET Apr 26 2017
    ETFs with exposure to Compugen Ltd. : April 25, 2017 Apr 25 2017
    Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program Mar 28 2017
    Compugen to Present CGEN-15001 Autoimmune Product Candidate at Upcoming Conferences Mar 22 2017
    Compugen Ltd. :CGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
    Compugen Ltd. :CGEN-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
    Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board Mar 08 2017
    Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery... Mar 02 2017
    Compugen Reports Fourth Quarter and Calendar Year 2016 Results Feb 15 2017
    Compugen Fourth Quarter and Yearend 2016 Conference Call Scheduled for Wednesday, February 15, 2017... Jan 30 2017
    Compugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity Jan 04 2017
    What Makes Compugen Ltd. (CGEN) a Strong Sell? Dec 20 2016
    Hedge Funds Are Dumping Voyager Therapeutics Inc (VYGR) Dec 18 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat